Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9533712 | 0.84 | TSHR (0.45) | ALDH1A1TSHRCYP3A4HSD17B10TDP1 | |
| SCHEMBL8768769 | 0.84 | GSK3B (0.55) | GSK3BALDH1A1HIF1AMAPK1TRPA1 | |
| SCHEMBL16010437 | 0.83 | CA12 (0.56) | GSK3BALDH1A1HIF1AMAPK1TRPA1 | |
| SCHEMBL29836035 | 0.83 | GSK3B (0.59) | GSK3BALDH1A1HIF1AMAPK1TRPA1 | |
| SCHEMBL5005689 | 0.83 | GSK3B (0.59) | GSK3BALDH1A1HIF1AMAPK1TRPA1 | |
| SCHEMBL43409 | 0.83 | CA12 (0.56) | GSK3BALDH1A1HIF1AMAPK1TRPA1 | |
| SCHEMBL29389757 | 0.83 | CA12 (0.56) | GSK3BALDH1A1HIF1AMAPK1TRPA1 | |
| SCHEMBL9618646 | 0.82 | TSHR (0.43) | ALDH1A1TSHRCYP3A4HSD17B10TDP1 | |
| Ethylene SCHEMBL27986952 | 0.80 | GSK3B (0.55) | GSK3BALDH1A1KDM4ETSHRKMO | |
| SCHEMBL11637468 | 0.79 | USP5 (0.50) | ALDH1A1HIF1ATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532455-B1 | IMPROVED SYNTHESIS OF MONO-CHLORINATED ACETOPHENONE | SIEGFRIED AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-3532455-B1 | IMPROVED SYNTHESIS OF MONO-CHLORINATED ACETOPHENONE | SIEGFRIED AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| US-20210107853-A1 | SYNTHESIS OF MONO-CHLORINATED ACETOPHENONE | SIEGFRIED AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-20210107853-A1 | SYNTHESIS OF MONO-CHLORINATED ACETOPHENONE | SIEGFRIED AG (CH) | 2021-04-15 | — | — | US | disclosed |
| EP-3498687-A1 | IMPROVED SYNTHESIS OF MONOCHLORINATED ACETOPHENONE | Siegfried AG (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-3498687-A1 | IMPROVED SYNTHESIS OF MONOCHLORINATED ACETOPHENONE | Siegfried AG (CH) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107853-A1 | SYNTHESIS OF MONO-CHLORINATED ACETOPHENONE | ACACA, CYP51A1, ACACB | GSK3B 3080/4885ALDH1A1 178/4885HIF1A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.